CytoSorbents Corporation · NASDAQ:CTSO
CytoSorbents — Q2 2016 Earnings Presentation
30 slides from CytoSorbents's earnings presentation, Aug 9, 2016
Slide 1: CytoSorbents Corporation Q2 2016 Earnings Conference Call
CytoSorbents Corporation (NASDAQ: CTSO) A Leader in Critical Care Immunotherapy Q2 2016 Earnings Conference Call August 9, 2016
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actu
Slide 3: CytoSorbents is A Leader in Critical Care Immunotherapy
CytoSorbents is A Leader in Critical Care Immunotherapy Leading the Prevention or Treatment of Life-Threatening Inflammation in the ICU and Cardiac Surgery using CytoSorb® Blood Purification 3
Slide 4: CytoSorb Removes the Fuel to the Fire
CytoSorb® Removes the Fuel to the Fire • CytoSorb® targets the $20+ billion opportunity in critical care and cardiac surgery • Approved in the European Union as the only specifically approved extracorporeal cytokine filter • Clinically proven to remove key cytokines in the blood of critically-ill pa
Slide 5: Goal: To Prevent or Treat Organ Failure
Goal: To Prevent or Treat Organ Failure Improve Decrease Patient Costs Of Outcome ICU and and Patient Survival Care Sepsis ARDS Burn Injury Trauma Pancreatitis Influenza Surgical The Potential to Revolutionize Critical Care Medicine 5
Slide 6: The World Needs CytoSorb
Suspect The World Needs CytoSorb® one m4 — x sim CvtOSoritents Working to Save Lives Through Blood Purification
Slide 7: Financial Highlights
Financial Highlights med CVtOSorbents forking to Save Lives Through Blood Purification
Slide 8: Q2 2016 Comparative Revenue Results
Q2 2016 Comparative Revenue Results 3 Months 3 Months Ended June Ended June 30, 2016 30, 2015 % Incr. Product revenue $ 1,852,670 $ 773,112 140% Grant and other income 369,668 190,827 94% Total revenue $ 2,222,338 $ 963,939 131% • CytoSorb® product sales were $1.9M for Q2 2016, a 140% increase over
Slide 9: Quarterly Product Sales
Quarterly Product Sales Fifth consecutive quarter of product sales growth Fourth consecutive quarter of record sales $2,000,000 CytoSorb® Product Sales $1,852,670 $1,800,000 $1,597,449 $1,600,000 $1,495,590 $1,400,000 $1,200,000 $1,071,459 $1,031,761 $1,000,000 $871,150 $800,000 $773,112 $703,658 $6
Slide 10: Comparative 6-Month Revenue Results
Comparative 6-Month Revenue Results 6 Months 6 Months Ended June Ended June 30, 2016 30, 2015 % Incr. Product revenue $ 3,450,119 $ 1,476,770 134% Grant and other income 582,401 210,243 177% Total revenue $ 4,032,520 $ 1,687,013 139% • CytoSorb® product sales for 1H 2016 were $3.5M, a 134% increase
Slide 11: Trailing Twelve Months Product Sales
Trailing Twelve Months Product Sales Over the past three years, the compound growth rate of return (“CAGR”) on product sales was 145% $8,000,000 Trailing Twelve Month Product Sales $7,000,000 $6,017,168 $6,000,000 $5,000,000 Trend Line $4,000,000 $3,379,681 $3,000,000 $2,000,000 $1,750,196 $1,000,00
Slide 12: CytoSorb Distributed in 37 Countries
CytoSorb® Distributed in 37 Countries IntensivMed WMC 12
Slide 13: Geographic Expansion – A Growth Engine
Geographic Expansion – A Growth Engine January 2016 August 2016 We continue to add new and existing distributors into the “contributing to revenue” category Canada coming on-line soon and many other countries 13
Slide 14: $10M Financing Facility from Bridge Bank
$10M Financing Facility from Bridge Bank • $5.0M term loan drawn down on June 30, 2016 provided $4.9M in net proceeds • The loan bears interest at the 30-day US dollar LIBOR rate plus 7.75%, which was 8.20% at June 30, 2016. The effective interest rate on the term loan (including all fees over the l
Slide 15: Working Capital and Cap Table
Working Capital and Cap Table Working Capital as of 6/30/16 12/31/15 12/31/14 12/31/13 12/31/12 Current Assets: Cash and short-term investments $ 8,919 $ 7,509 $ 5,550 $ 2,183 $ 1,729 Grants and accounts receivable, net 945 649 819 453 51 Inventories 1,048 1,191 538 245 682 Prepaid expenses and othe
Slide 16: Operating Highlights
Operating Highlights med CVtOSorbents forking to Save Lives Through Blood Purification
Slide 17: REFRESH I Trial Update
REFRESH I Trial Update REduction in FREe Hemoglobin • 40-patient, eight-center study evaluating the safety and efficacy of intra-operative use of CytoSorb® in a heart-lung machine during complex cardiac surgery in elective, non-emergent cardiac surgery > 3 hours • Aortic reconstruction, CABG redos,
Slide 18: REFRESH I Trial Update
REFRESH I Trial Update REduction in FREe Hemoglobin Trial • Working with major cardiac surgery centers • Baylor College of Medicine and Texas Heart Institute • Baystate Medical Center • Columbia University • Cooper University Hospital • University of Kentucky • University of Maryland • University of
Slide 19: Fresenius Medical Care Partnership
Fresenius Medical Care Partnership • Entered into a multi-year partnership with Fresenius, the world’s largest dialysis company, for exclusive distribution of CytoSorb® in critical care in France, Poland, Denmark, Norway, Sweden, and Finland • CytoSorb® is a key part of Fresenius’ growth strategy in
Slide 20: FMC is Actively Marketing and Selling
FMC is Actively Marketing and Selling Fresenius is actively marketing and selling CytoSorb in its market countries, and has a busy schedule in actively promoting CytoSorb in upcoming critical care conferences Fresenius multiFitrate Pro 20
Slide 21: Marketing Collateral
Marketing Collateral Product Brochure (9 pages) 21
Slide 22: Partnership Update
Partnership Update Treat Primary Infection Treat Massive Inflammatory with Antibiotics Response • Biocon is the largest biopharmaceutical company in India • Significant growth in India with expansion into Sri Lanka • Currently funding and conducting the first investigator initiated study in India •
Slide 23: $18 Million in U.S. Government Support
$18 Million in U.S. Government Support • DARPA awarded $3.8M five year (2012-present) contract as part of “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins • U.S. Army awarded ~$1.7M SBIR contracts for trauma and burn injury research and hyperkale
Slide 24: Potassium Binding Polymer Program
Potassium Binding Polymer Program • We were recently awarded a total of approximately $650K in Small Business Innovation Research (SBIR) contracts to continue development of novel potassium (K+) binding polymers • ~$500K Phase II Enhancement increasing our previous $1.15M U.S. Army Phase I and II SB
Slide 25: Visit CytoSorb.com for Case of the Week
Visit CytoSorb.com for Case of the Week • We have had excellent feedback from both physicians and investors on the many exciting case reports presented in the CytoSorb “Case of the Week” on the www.cytosorb.com website • These cases highlight the ongoing successes that clinicians continue to have as
Slide 26: Case Report: Septic Shock from UTI
Case Report: Septic Shock from UTI • 75 yo man with a history of surgery for urinary tract cancer, developed a urinary tract infection after replacement of a ureteral stent designed to conduct urine from the ureters outside the body (urostomy) • Diagnosed with an E. coli infection and despite broad
Slide 27: Case Report: Swine Flu & PVL+Staph Pneumonia
Case Report: Swine Flu & PVL+Staph Pneumonia • A previously healthy 33 yo woman, 5 months after giving birth, presented with a 4-day history of flu- like symptoms, who presented with breathlessness, confusion, and chest and abdominal pain • At ICU admission, diagnosed with H1N1 influenza complicated
Slide 28: Outlook for 2H 2016
Outlook for 2H 2016 • CytoSorbents has not historically given financial guidance on quarterly results until the quarter has been completed. • However, we currently expect a strong second half of 2016, with the achievement of numerous operating milestones • In addition, we expect that second half 201
Slide 29: CytoSorb SIRS and Sepsis: Regain Control!
CytoSorb® SIRS and Sepsis: Regain Control! 29
Slide 30: Q&A Session
Q&A Session CytoSorbents Corporation NASDAQ: CTSO Phillip P. Chan, MD, PhD - CEO 7 Deer Park Drive, Suite K Monmouth Junction, NJ 08852 [email protected] A Leader in Critical Care Immunotherapy 30